ImmunityBio Inc (IBRX)
7.35
+2.24
(+43.84%)
USD |
NASDAQ |
Apr 26, 16:00
7.63
+0.28
(+3.81%)
After-Hours: 20:00
ImmunityBio Debt to Equity Ratio: -1.161 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.161 |
| September 30, 2023 | -1.636 |
| June 30, 2023 | -1.197 |
| March 31, 2023 | -1.356 |
| December 31, 2022 | -1.505 |
| September 30, 2022 | -1.549 |
| June 30, 2022 | -1.459 |
| Date | Value |
|---|---|
| March 31, 2022 | -1.814 |
| December 31, 2021 | -2.501 |
| September 30, 2021 | -1.609 |
| June 30, 2021 | -1.901 |
| March 31, 2021 | -1.600 |
| December 31, 2020 | -2.123 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-2.501
Minimum
Dec 2021
-1.161
Maximum
Dec 2023
-1.647
Average
-1.600
Median
Mar 2021
Debt to Equity Ratio Benchmarks
| Geron Corp | 0.3305 |
| Madrigal Pharmaceuticals Inc | -- |
| Vanda Pharmaceuticals Inc | 0.00 |
| iBio Inc | -- |
| Chromocell Therapeutics Corp | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 504.45M |
| Total Liabilities (Quarterly) | 1.090B |
| Shareholders Equity (Quarterly) | -586.99M |
| Current Ratio | 5.046 |
| Net Debt Paydown Yield | -0.12% |